Q32 Bio Stock Current Asset

QTTB Stock   26.91  0.01  0.04%   
Q32 Bio fundamentals help investors to digest information that contributes to Q32 Bio's financial success or failures. It also enables traders to predict the movement of Q32 Stock. The fundamental analysis module provides a way to measure Q32 Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Q32 Bio stock.
The current year's Non Current Assets Total is expected to grow to about 233.3 M. The current year's Other Current Assets is expected to grow to about 1.8 M.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Q32 Bio Company Current Asset Analysis

Q32 Bio's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Current Asset

 = 

Cash

+

Deposits

+

Liquid Assets

More About Current Asset | All Equity Analysis

Q32 Current Asset Historical Pattern

Today, most investors in Q32 Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Q32 Bio's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Q32 Bio current asset as a starting point in their analysis.
   Q32 Bio Current Asset   
       Timeline  
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
Competition

Q32 Total Assets

Total Assets

190.88 Million

At present, Q32 Bio's Total Assets are projected to increase significantly based on the last few years of reporting.
In accordance with the recently published financial statements, Q32 Bio has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.

Q32 Current Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Q32 Bio's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Q32 Bio could also be used in its relative valuation, which is a method of valuing Q32 Bio by comparing valuation metrics of similar companies.
Q32 Bio is currently under evaluation in current asset category among its peers.

Q32 Bio Current Valuation Drivers

We derive many important indicators used in calculating different scores of Q32 Bio from analyzing Q32 Bio's financial statements. These drivers represent accounts that assess Q32 Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Q32 Bio's important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap871.8M518.3M201.2M35.2M40.4M38.4M
Enterprise Value818.1M316.3M174.0M(2.8M)(3.2M)(3.1M)

Q32 Fundamentals

About Q32 Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Q32 Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Q32 Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Q32 Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Q32 Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Q32 Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Q32 Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Q32 Bio Stock:
Check out Q32 Bio Piotroski F Score and Q32 Bio Altman Z Score analysis.
For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Q32 Bio. If investors know Q32 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Q32 Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.50)
Revenue Per Share
(1.24)
The market value of Q32 Bio is measured differently than its book value, which is the value of Q32 that is recorded on the company's balance sheet. Investors also form their own opinion of Q32 Bio's value that differs from its market value or its book value, called intrinsic value, which is Q32 Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Q32 Bio's market value can be influenced by many factors that don't directly affect Q32 Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Q32 Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Q32 Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Q32 Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.